Evidence map›Paper›PMID 28659343›Full record

ArticleThe Journal of biological chemistry2017

The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles.

Birthe Trautz, Hannah Wiedemann, Christian Lüchtenborg, Virginia Pierini, Jan Kranich, Bärbel Glass, Hans-Georg Kräusslich, Thomas Brocker, Massimo Pizzato, Alessia Ruggieri and 2 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. HIV-1 restriction by SERINC5.Medical microbiology and immunology · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Birthe TrautzFrom the Department of Infectious Diseases, Integrative Virology, and.
Hannah Wiedemannthe Heidelberg University Biochemistry Center, INF 328, 69120 Heidelberg, Germany.
Christian Lüchtenborgthe Heidelberg University Biochemistry Center, INF 328, 69120 Heidelberg, Germany.
Virginia PieriniFrom the Department of Infectious Diseases, Integrative Virology, and.
Jan Kranichthe Institute for Immunology, Ludwig-Maximilians-Universität München, Groβhardener Straße 9, 82152 Planegg-Martinsried, Germany.
Bärbel GlassDepartment of Infectious Diseases, Virology, University Hospital Heidelberg, INF 324, 69120 Heidelberg, Germany.
Hans-Georg KräusslichDepartment of Infectious Diseases, Virology, University Hospital Heidelberg, INF 324, 69120 Heidelberg, Germany.
Thomas Brockerthe Institute for Immunology, Ludwig-Maximilians-Universität München, Groβhardener Straße 9, 82152 Planegg-Martinsried, Germany.
Massimo Pizzatothe University of Trento, Centre for Integrative Biology, 38122 Trento, Italy, and.
Alessia Ruggierithe Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, INF 345, 69120 Heidelberg, Germany.
Britta Brüggerthe Heidelberg University Biochemistry Center, INF 328, 69120 Heidelberg, Germany, britta.bruegger@bzh.uni-heidelberg.de.
Oliver T FacklerFrom the Department of Infectious Diseases, Integrative Virology, and oliver.fackler@med.uni-heidelberg.de.
Heidelberg University · DELudwig-Maximilians-Universität München · DEUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The host-cell restriction factor SERINC5 potently suppresses the infectivity of HIV, type 1 (HIV-1) particles, and is counteracted by the viral pathogenesis factor Nef. However, the molecular mechanism by which SERINC5 restricts HIV-1 particle infectivity is still unclear. Because SERINC proteins have been suggested to facilitate the incorporation of serine during the biosynthesis of membrane lipids and because lipid composition of HIV particles is a major determinant of the infectious potential of the particles, we tested whether SERINC5-mediated restriction of HIV particle infectivity involves alterations of membrane lipid composition. We produced and purified HIV-1 particles from SERINC5293T cells with very low endogenous SERINC5 levels under conditions in which ectopically expressed SERINC5 restricts HIV-1 infectivity and is antagonized by Nef and analyzed both virions and producer cells with quantitative lipid MS. SERINC5 restriction and Nef antagonism were not associated with significant alterations in steady-state lipid composition of producer cells and HIV particles. Sphingosine metabolism kinetics were also unaltered by SERINC5 expression. Moreover, the levels of phosphatidylserine on the surface of HIV-1 particles, which may trigger uptake into non-productive internalization pathways in target cells, did not change upon expression of SERINC5 or Nef. Finally, saturating the phosphatidylserine-binding sites on HIV target cells did not affect SERINC5 restriction or Nef antagonism. These results demonstrate that the restriction of HIV-1 particle infectivity by SERINC5 does not depend on alterations in lipid composition and organization of HIV-1 particles and suggest that channeling serine into lipid biosynthesis may not be a cardinal cellular function of SERINC5.

Indexed as

Lipid MetabolismAntigens, SurfaceBinding, CompetitiveCell Line, TumorGene DeletionGreen Fluorescent ProteinsHEK293 CellsHIV-1HumansKineticsLiposomesMembrane ProteinsMilk Proteinsnef Gene Products, Human Immunodeficiency VirusPeptide FragmentsPhosphatidylserinesAntigens, SurfaceGreen Fluorescent ProteinsLiposomesMembrane ProteinsMFGE8 protein, humanMilk Proteinsnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1Peptide FragmentsPhosphatidylserinesRecombinant Fusion ProteinsSERINC5 protein, humanSphingosinehost cell restriction factorhost-pathogen interactionhuman immunodeficiency virus (HIV)infectious diseaselipidlipid compositionNefSERINC5viral protein

Identifiers

PMID28659343
PMCPMC5566525
OpenAlexW2734055064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.